All questions
Clinical trials: Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration 5 questions · 5 sources
Questions that apply to every indication of Vabysmo are on Vabysmo (faricimab-svoa), all indications .
Clinical trials How were the Vabysmo wet AMD trials (TENAYA and LUCERNE) designed? Note: The second Prescribing Information passage continues the sentence that ends the first, across a page break of the label.
Study results How well does Vabysmo work vs aflibercept for wet AMD (TENAYA, LUCERNE)? Note: Table 2 columns are VABYSMO and aflibercept in TENAYA, then VABYSMO and aflibercept in LUCERNE, in that order.
How many wet AMD patients were on Vabysmo every 16 weeks at week 48? “At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the
Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the
remaining 22% of patients received dosing every 8 weeks. These percentages are reflective of
what happened within the conduct of these trials and indicate that some patients did well on two
(2) doses spaced 16 weeks apart, or three (3) doses spaced 12 weeks apart, but the percentages
may not be generalizable to a broader nAMD population for a variety of reasons. The
inclusion/exclusion criteria limited enrollment to a select subset of treatment-naïve, newly
diagnosed nAMD patients and there is no empirical data that a similar magnitude would be
observed if eligibility criteria allowed for broader enrollment. The disease activity criteria, which
was instrumental in determining dose frequency, is unvalidated. Stricter criteria would have
changed how patients were treated resulting in different percentages of subjects in each dose
interval cohort. There was not a similarly dosed aflibercept arm for comparison, which makes the
percentages difficult to interpret.” (opens the source at this quote in a new tab) Copy Flag
Does Vabysmo reduce retinal thickness (CST) in wet AMD trials? Note: The drying page of the VABYSMO HCP site presents the nAMD central subfield thickness (CST) results as a graph; the quoted text is the assessment and limitations statement printed with it.
Subgroup results Were Vabysmo wet AMD results consistent across age, sex, race, and baseline vision?